Circulating factor in FSGS: a black sheep in the suPAR family?
Circulating factor in FSGS: a black sheep in the suPAR family?
复制标题
FSGS 中的循环因子：suPAR 家族中的害群之马？
DOI：
10.1007/s00467-013-2463-2
复制
发表时间：
2013
期刊：
影响因子：
--
通讯作者：
Reiser,Jochen
中科院分区：
文献类型：
--
作者：
Trachtman,Howard;Wei,Changli;Reiser,Jochen
在本期《儿科肾脏病学》中，Maas及其同事总结了可溶性尿激酶型纤溶酶原激活物受体（suPAR）在局灶性和节段性肾小球硬化（FSGS）中作用的最新进展[1]。在大多数患有FSGS的儿童和成人患者中以及在响应于致病性suPAR片段而发生肾小球病的动物模型中，总suPAR水平升高的观察结果引发了对这种重要疾病的创新研究，该疾病具有相当大的未满足的医疗需求。事实上，最近发表了更多的数据，评估了FSGS中的suPAR，并证实了这种肾小球疾病中循环分子之间的联系。
Sirs, In this edition of Pediatric Nephrology, Maas and colleagues summarize the recent progress on the role of soluable urokinase-type plasminogen activator receptor (suPAR) in focal and segmental glomerulosclerosis (FSGS)[1]. The observation that total suPAR levels are elevated in the majority of pediatric and adult patients with FSGS as well as in animal models that develop glomerulopathy in response to pathogenic suPAR fragments has sparked innovative research in this important disease with considerable unmet medical needs. Indeed, more data have recently been published that evaluated suPAR in FSGS and confirm a link between the circulating molecule in this glomerular disorder.